Illumina closed its acquisition of SomaLogic and related assets from Standard BioTools, paying $350 million in cash plus up to $75 million in near‑term milestones and royalties. The deal brings SomaLogic’s SomaScan aptamer proteomics technology and a CLIA/CAP lab in Boulder into Illumina’s portfolio and is intended to accelerate sequencing‑based protein readouts and integrated multiomics workflows. Illumina said it will leverage its NGS ecosystem, DRAGEN software and Protein Prep assay efforts to scale protein analysis and integrate proteomics into its Connected Multiomics strategy. The firm indicated no immediate operational changes in Boulder and framed the acquisition as a way to offer higher‑throughput, more affordable protein analysis to researchers and diagnostics developers. Company disclosures and coverage note Illumina’s positioning of proteomics as a commercial and scientific growth area that complements its core sequencing business.